Cumulative In-Hospital Costs Associated With Single-Ventricle Palliation

Michael L. O'Byrne, Kimberly E. McHugh, Jing Huang, Lihai Song, Heather Griffis, Brett R. Anderson, Emily M. Bucholz, Nikhil K. Chanani, Justin J. Elhoff, Stephanie S. Handler, Jeffery P. Jacobs, Jennifer S. Li, Alan B. Lewis, Brian W. McCrindle, Nelangi M. Pinto, Peter Sassalos, David S. Spar, Sara K. Pasquali, Andrew C. Glatz

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: In the SVR (Single Ventricle Reconstruction) Trial, 1-year survival in recipients of right ventricle to pulmonary artery shunts (RVPAS) was superior to that in those receiving modified Blalock-Taussig-Thomas shunts (MBTTS), but not in subsequent follow-up. Cost analysis is an expedient means of evaluating value and morbidity. Objectives: The purpose of this study was to evaluate differences in cumulative hospital costs between RVPAS and MBTTS. Methods: Clinical data from SVR and costs from Pediatric Health Information Systems database were combined. Cumulative hospital costs and cost-per-day-alive were compared serially at 1, 3, and 5 years between RVPAS and MBTTS. Potential associations between patient-level factors and cost were explored with multivariable models. Results: In total, 303 participants (55% of the SVR cohort) from 9 of 15 sites were studied (48% MBTTS). Observed total costs at 1 year were lower for MBTTS ($701,260 ± 442,081) than those for RVPAS ($804,062 ± 615,068), a difference that was not statistically significant (P = 0.10). Total costs were also not significantly different at 3 and 5 years (P = 0.21 and 0.32). Similarly, cost-per-day-alive did not differ significantly for either group at 1, 3, and 5 years (all P > 0.05). In analyses of transplant-free survivors, total costs and cost-per-day-alive were higher for RVPAS at 1 year (P = 0.05 for both) but not at 3 and 5 years (P > 0.05 for all). In multivariable models, aortic atresia and prematurity were associated with increased cost-per-day-alive across follow-up (P < 0.05). Conclusions: Total costs do not differ significantly between MBTTS and RVPAS. The magnitude of longitudinal costs underscores the importance of efforts to improve outcomes in this vulnerable population.

Original languageEnglish
Article number100029
JournalJACC: Advances
Issue number2
StatePublished - Jun 2022


  • economic analysis
  • hypoplastic left heart syndrome
  • outcomes research
  • pediatrics


Dive into the research topics of 'Cumulative In-Hospital Costs Associated With Single-Ventricle Palliation'. Together they form a unique fingerprint.

Cite this